| |
IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management.
|
|
Today’s Big NewsOct 15, 2024 |
|
Patient perspectives, priorities, and preferences – Without these criteria, designing truly patient-centric rare disease trials is impossible. Turn up the volume of the patient voice on your next study with the help of our guide.
|
|
| By Fraiser Kansteiner Pfizer is laying out $49 million up front in a partnership and licensing pact with Massachusetts-based Triana Biomedicines to discover molecular glue degraders for cancer and other conditions. The deal could ultimately be worth more than $1.5 billion, thanks to potential royalties and milestones. |
|
|
|
By James Waldron Forbion has unveiled its largest fundraising haul to date, as the European life-sciences-focused VC firm brings in over 2 billion euros across two funds. |
By Nick Paul Taylor Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized myasthenia gravis to the growing case for its near-approval FcRn blocker. |
Sponsored by Cryoport Systems Discover how Cryoport Systems is revolutionizing gene therapy logistics with its Elite Ultra Cold shipping system. Learn about extended hold times, enhanced security and real-time monitoring designed to protect high-value therapies in transit. |
|
Cryoport Systems' temperature-controlled supply chain solutions, including biostorage, drug labelling, kit production, cryopreservation & consulting were built with scalability in mind, Enabling The Outcome™️ for patients around the world. Learn More.
|
|
By James Waldron Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the cancer-focused platform company’s decision to file for bankruptcy. |
Sponsored by Travere Therapeutics When a specialized field of medicine has long been quiet, a buzz of breakthrough can seem like a sudden development. The reality is more nuanced. |
By Darren Incorvaia Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial of patients with type 2 diabetes, the company announced in an Oct. 15 release. |
By Darren Incorvaia MeiraGTx is looking to march their Parkinson’s treatment forward after the gene therapy improved motor ability and quality of life in a small phase 2 trial. The treatment, AAV-GAD, also led to no serious adverse events, the company said in an Oct. 15 release. |
By Gabrielle Masson Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ. |
By Nick Paul Taylor Topas Therapeutics has hailed a win for its immune-tolerance platform, reporting positive phase 2a data on its celiac disease candidate without sharing numbers to validate its upbeat outlook. |
By James Waldron Ocean Biomedical hopes the preclinical YKL-40 inhibitors have potential against cancers, as well as inflammatory and fibrotic diseases. |
By Angus Liu Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it could prolong patients’ lives in extensive-stage small cell lung cancer. |
By Joseph Keenan Baxter International, which was forced by flooding from Hurricane Helene to temporarily halt production at its North Carolina facility, has started importing intravenous fluids from foreign facilities to help alleviate a U.S. shortage of essential medical supplies. |
By Heather Landi Walgreens reported a loss of $3 billion in the fourth quarter and plans to close 1,200 stores over the next three years as part of the retail drugstore chain's ongoing turnaround strategy amid a rocky fiscal 2024. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
| eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
| WhitepaperTake a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
| WhitepaperUnlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
| WhitepaperFinding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
